Lu AF11167 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses Lu AF11167 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Lu AF11167
- 5
Studies by the year they started
5 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses Lu AF11167 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative SymptomsTerminatedPhase 2H. Lundbeck A/SNCT03929497Written as Lu AF11167
- A Study Investigating Tablet Formulations of Lu AF11167 in Healthy SubjectsCompletedPhase 1H. Lundbeck A/SNCT04104503Written as Lu AF11167
- Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.CompletedPhase 1H. Lundbeck A/SNCT02199431Written as Lu AF11167
- Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167CompletedPhase 1H. Lundbeck A/SNCT02260830Written as Lu AF11167
- Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With SchizophreniaCompletedPhase 1H. Lundbeck A/SNCT02202213Written as Lu AF11167